UiPath (NYSE:PATH) Price Target Increased to $15.00 by Analysts at BMO Capital Markets

UiPath (NYSE:PATH) had its price objective boosted by BMO Capital Markets from $14.00 to $15.00 in a research note published on Friday morning, Benzinga reports. They currently have a market perform rating on the healthcare company’s stock.

A number of other research firms have also weighed in on PATH. KeyCorp reissued a sector weight rating on shares of UiPath in a research note on Thursday, May 30th. Mizuho cut their target price on UiPath from $25.00 to $14.00 and set a neutral rating for the company in a research note on Thursday, May 30th. Morgan Stanley lowered their price target on shares of UiPath from $25.00 to $15.00 and set an equal weight rating on the stock in a research report on Thursday, May 30th. JPMorgan Chase & Co. decreased their target price on shares of UiPath from $28.00 to $19.00 and set an overweight rating on the stock in a report on Thursday, May 30th. Finally, Truist Financial restated a hold rating and set a $14.00 price target (down previously from $32.00) on shares of UiPath in a report on Thursday, May 30th. Sixteen investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, UiPath currently has an average rating of Hold and a consensus price target of $17.71.

UiPath Stock Performance

UiPath stock opened at $11.98 on Friday. The company’s fifty day moving average price is $12.20 and its 200 day moving average price is $16.71. UiPath has a 1 year low of $10.37 and a 1 year high of $27.87. The stock has a market capitalization of $6.86 billion, a P/E ratio of -74.84 and a beta of 0.87.

UiPath (NYSE:PATH) last issued its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. The firm had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. During the same period in the previous year, the business earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. Sell-side analysts predict that UiPath will post -0.22 EPS for the current year.

Hedge Funds Weigh In On UiPath

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC lifted its stake in UiPath by 3.1% in the fourth quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock worth $356,000 after acquiring an additional 426 shares during the last quarter. Global Financial Private Client LLC increased its holdings in UiPath by 9.3% in the first quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after buying an additional 551 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in UiPath by 1.7% during the 1st quarter. Principal Financial Group Inc. now owns 36,772 shares of the healthcare company’s stock worth $834,000 after buying an additional 622 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of UiPath by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after acquiring an additional 632 shares in the last quarter. Finally, Lindbrook Capital LLC raised its position in shares of UiPath by 46.0% during the 1st quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after acquiring an additional 639 shares in the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.